A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
SANTA CLARA, CA – November 19, 2025 – Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced that its Board of Directors has declared a quarterly dividend of 25.5 cents per share of common stock. This latest declaration underscores the company's robust
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized treatment. By intelligently integrating diverse data types—from medical imaging and genomic profiles to clinical notes and real-world patient data—these advanced AI systems offer a holistic and nuanced understanding of [...]
The financial markets are once again in the throes of earnings season, a period that consistently proves to be a crucible for individual stock valuations and a significant driver of broader market sentiment. Recent corporate earnings reports, spanning from late 2024 through the third quarter of 2025, have painted a
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates.
Life sciences company Bio-Techne (NASDAQ:TECH)
will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment firm raised its price target on Bio-Techne to $62 from $53. The stock's rise also occurred as the broader market showed strength. Stocks rose after solid earnings reports from major tech companies like Apple and Amazon beat expectations, which seemed to spark a rally in the sector. Bio-Techne's move followed a recent period of volatility, which included a sharp surge of over 18% in the preceding month.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
While the S&P 500 is up 26.5% since April 2025, Bio-Techne (currently trading at $59.58 per share) has lagged behind, posting a return of 19.2%. This may have investors wondering how to approach the situation.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
